Clinical Data Data could move J&J’s Talvey earlier in myeloma therapy PharmaphorumJohnson Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.HematologyRead full story pharminent June 15, 2026 (Last updated: June 15, 2026) Pharmaphorum Johnson Johnson’s Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatmentNext: Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy Related Stories Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026 Clinical Data Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes pharminent June 30, 2026
